Literature DB >> 26185135

Impact of O6-methylguanine-DNA methyltransferase expression on the drug resistance of clear cell renal cell carcinoma.

Nan Ge1, Liqiang Guo1, Jie Zhang1, Zhaomin Lin2, Yan Li3, Yuqiang Liu1, Feng Kong2, Xiaolei Fang1, Shengtian Zhao4.   

Abstract

OBJECTIVE: The deoxyribonucleic acid-repair protein O(6)-methylguanine-deoxyribonucleic acid methyltransferase is a major determinant of resistance of cells to various alkylating drugs. Its expression profile is different in different cancer types. Here, we studied the expression and function of O(6)-methylguanine-deoxyribonucleic acid methyltransferase in clear cell renal cell carcinoma.
METHODS: The expression of O(6)-methylguanine-deoxyribonucleic acid methyltransferase was evaluated in clear cell renal cell carcinoma tissues and cell lines by quantitative real-time polymerase chain reaction and immunohistochemistry. The relationship between O(6)-methylguanine-deoxyribonucleic acid methyltransferase expression and clinicopathological characteristics was analyzed. To further investigate the function of O(6)-methylguanine-deoxyribonucleic acid methyltransferase in clear cell renal cell carcinoma resistance to alkylating agents, siRNA targeting O(6)-methylguanine-deoxyribonucleic acid methyltransferase were used to silence the O(6)-methylguanine-deoxyribonucleic acid methyltransferase expression.
RESULTS: We found that O(6)-methylguanine-deoxyribonucleic acid methyltransferase is over-expressed in clear cell renal cell carcinoma tissues and cell lines. O(6)-methylguanine-deoxyribonucleic acid methyltransferase expression is related with tumor progression in clear cell renal cell carcinoma patients. Up-regulation of O(6)-methylguanine-deoxyribonucleic acid methyltransferase plays a critical role in primary resistance to alkylating agents.
CONCLUSIONS: The overexpression of O(6)-methylguanine-deoxyribonucleic acid methyltransferase contributes to resistance of clear cell renal cell carcinoma to standard chemotherapy. Our results have significance for understanding a new pathway of the development of drug resistance of clear cell renal cell carcinoma.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  MGMT; alkylating agents; clear cell renal cell carcinoma

Mesh:

Substances:

Year:  2015        PMID: 26185135     DOI: 10.1093/jjco/hyv095

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

Review 1.  New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy.

Authors:  Kevin Zarrabi; Chunhui Fang; Shenhong Wu
Journal:  J Hematol Oncol       Date:  2017-02-02       Impact factor: 17.388

2.  GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.

Authors:  Hsiao-Han Wang; Tsuey-Yu Chang; Wei-Chen Lin; Kuo-Chen Wei; Jyh-Wei Shin
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

Review 3.  Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?

Authors:  Leonardo Marques da Fonseca; Vanessa Amil da Silva; Leonardo Freire-de-Lima; José Osvaldo Previato; Lucia Mendonça-Previato; Márcia Alves Marques Capella
Journal:  Front Oncol       Date:  2016-06-22       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.